Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Carteolol/Latanoprost vs Timolol/Latanoprost Fixed Combination in Glaucoma
jRCTs031180071Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Feb 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised trial of Carteolol, timolol and latanoprost in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: Daily fluctuation of intraocular pressure. Started Feb 2019; status: completed.
02
Drugs
Carteololtimolollatanoprost
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on jRCTs031180071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180071.